SCHEMBL77677

SCHEMBL77677

Cc1ccc(S(=O)(=O)N[C@@H](CCCCN)C(=O)O)cc1.O=C(CCl)CCl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 12/20 0.67
MMP2 P08253 11/20 0.67
ITGB3 P05106 1/20 0.53
ITGA2B P08514 1/20 0.53
TDP1 Q9NUW8 1/20 0.50
SLC1A3 P43003 1/20 0.47
SLC1A2 P43004 1/20 0.47
SLC1A1 P43005 1/20 0.47
MMP13 P45452 2/20 0.47
MMP3 P08254 1/20 0.47
MMP8 P22894 4/20 0.45
ADAMTS4 O75173 1/20 0.45
PLAU P00749 1/20 0.45
HPN P05981 1/20 0.45
MMP12 P39900 3/20 0.45
MMP14 P50281 3/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2038720 1.00 MMP9 (0.67) MMP9MMP2ITGB3ITGA2BTDP1
Hydrochloric Acid SCHEMBL1499337 0.99 MMP9 (0.65) MMP9MMP2ITGB3ITGA2BTDP1
Hydrochloric Acid SCHEMBL14059214 0.99 MMP9 (0.65) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL457772 0.93 MMP9 (0.76) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL10585071 0.93 MMP9 (0.76) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL8001084 0.93 MMP9 (0.76) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL8322406 0.92 MMP9 (0.71) MMP9MMP2ITGB3ITGA2BTDP1
Hydrochloric Acid SCHEMBL9087107 0.92 MMP9 (0.74) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL232590 0.91 MMP9 (0.70) MMP9MMP2ITGB3ITGA2BTDP1
SCHEMBL796113 0.91 MMP9 (0.70) MMP9MMP2ITGB3ITGA2BTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 527 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12458582-B2 Stabilized hyaluronic acid CROMA-PHARMA GMBH (AT) 2025-11-04 US claimed
EP-3806918-A1 STABILIZED HYALURONIC ACID Croma-Pharma Gesellschaft m.b.H. (AT) 2021-04-21 EP claimed
WO-2019238955-A1 STABILIZED HYALURONIC ACID CROMA-PHARMA GMBH (AT) 2019-12-19 WO claimed
US-8257327-B2 Wound cleansing apparatus with actives SMITH & NEPHEW PLC (GB) 2012-09-04 US claimed
US-20110263521-A1 PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-10-27 US claimed
US-20100323985-A1 PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-12-23 US claimed
US-20100298249-A1 PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-11-25 US claimed
US-20100249733-A9 APPARATUS WITH ACTIVES FROM TISSUE SMITH & NEPHEW PLC (GB) 2010-09-30 US claimed
EP-1562668-B1 Medical apparatus for irrigating wounds SMITH & NEPHEW (GB) 2009-12-02 EP claimed
US-7524315-B2 Apparatus for aspirating, irrigating and cleansing wounds SMITH & NEPHEW PLC (GB) 2009-04-28 US claimed
US-6635802-B1 Culturing mammalian cell population in serum starvation media containing apoptosis inhibitor to increase number of cells at G0/G1 stage of cell cycle within cell population, increasing number of nuclear transfer competent cells THE TEXAS A&M UNIVERSITY SYSTEM 2003-10-21 US claimed
EP-1352627-A2 Reduction of hair growth THE GILLETTE COMPANY (US) 2003-10-15 EP claimed
EP-0863741-A2 REDUCTION OF HAIR GROWTH HANDELMAN, Joseph H. (US) 1998-09-16 EP claimed
US-5652273-A APPLYING HEXOKINASE INHIBITOR TO SKIN GILLETTE COMPANY THE 1997-07-29 US claimed
WO-1997019673-A2 REDUCTION OF HAIR GROWTH HANDELMAN, JOSEPH, H. (US) 1997-06-05 WO claimed
US-5532142-A PROTEINS FOR GENETIC ENGINEERING WITH DNA USING PROTEINASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1996-07-02 US claimed
WO-1995004155-A2 A METHOD FOR SYNTHESIS OF POLYSACCHARIDES BROWN MALCOLM R JR (US) 1995-02-09 WO claimed
US-4687666-A N-PARA-TOSYL-L-LYSINE CHLOROMETHYL KETONE MINISTERIO DE SANIDAD Y ASISTENCIA SOCIAL INSTITUTO VENEZOLANO DE INVESTIGATIONES CIENTIFICAS (VE) 1987-08-18 US claimed
US-12458582-B2 Stabilized hyaluronic acid CROMA-PHARMA GMBH (AT) 2025-11-04 US disclosed
EP-0066786-B1 METHOD OF PRODUCING A COLON SPECIFIC ANTIGEN P TRYPTIC PEPTIDE AND ANTI-COLON SPECIFIC ANTIGEN P ANTIBODIES Goldenberg, Milton David (US) 1986-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458582-B2 Stabilized hyaluronic acid CD44, HSPH1, ACR MMP9 133/4885MMP2 106/4885ITGB3 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.